関連する実験動画
Updated: Jan 18, 2026

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.2K
GLP1受容体作動薬と周術期管理の考慮事項:ナラティブレビュー
A Vázquez Lima1, M Vidal Lopo1
1Servicio de Anestesiología y Reanimación, Complejo Hospitalario Universitario de Vigo, Vigo (Pontevedra), Spain.
Revista espanola de anestesiologia y reanimacion
|January 15, 2026
まとめ
グルカゴン様ペプチド-1(GLP-1)アナログは、合併症を増加させることなく、手術中の血糖コントロールを最適化します。しかし、胃排出遅延は気管支吸引のリスクを軽減するための対策を必要とします。
科学分野:
- 薬理学
- 内分泌学
- 麻酔科学
背景:
- グルカゴン様ペプチド-1アナログ(GLP-1 RA)は、血糖恒常性の維持に不可欠です。
- その膵臓および膵外作用は、麻酔への影響と周術期管理に影響を与えます。
- 長期的な休薬効果と免疫調節作用については、さらなる解明が必要です。
研究 の 目的:
- GLP-1 RAの周術期への影響をレビューすること。
- 血糖コントロールと外科的転帰への影響を評価すること。
- 周術期GLP-1 RA使用に関連するリスクと管理戦略を特定すること。
主な方法:
- 既存の文献のナラティブレビュー。
- GLP-1 RAの膵臓および膵外作用の分析。
- 周術期管理戦略と潜在的な合併症の評価。
主要な成果:
- 周術期GLP-1 RAの使用は、血糖コントロールの改善と関連しています。
- 術後の合併症の有意な増加は観察されませんでした。
- 胃排出遅延は注目すべき副作用であり、気管支吸引のリスクを高める可能性があります。
結論:
- 周術期にGLP-1 RAを維持することは、血糖コントロールと治療上の利点を最適化します。
- 胃排出遅延と気管支吸引のリスクは、慎重な患者管理を必要とします。
- 現在のエビデンスは、適切なリスク軽減策を講じた上での安全な周術期使用を示唆しています。
関連する概念動画
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Oral Hypoglycemic Agents: Biguanides and Glitazones
587
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
587
Hypoglycemia and Glucagon
838
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
838

